• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Lrp5/6 在心脏瓣膜病中的作用:载脂蛋白 E 基因敲除 /Lrp5 基因敲除小鼠的实验性高胆固醇血症。

The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/- /Lrp5-/- mice.

机构信息

Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

出版信息

J Cell Biochem. 2011 Oct;112(10):2987-91. doi: 10.1002/jcb.23221.

DOI:10.1002/jcb.23221
PMID:21678468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3263342/
Abstract

Lrp5/6 co-receptor is known to play a role in bone formation and lipid metabolism. This gene encodes a member of the low-density lipoprotein (LDL) receptor gene family. This study tests the hypothesis that Lrp5/6 is necessary for the development of valve calcification in experimental hypercholesterolemia. Experimental hypercholesterolemia mouse models were tested: Lrp5(-/-) /ApoE(-/-):Lrp5(-/-) /ApoE(-/-) mice (n = 180). Group I (n = 60) normal diet, Group II (n = 60) 0.25% chol diet (w/w), and Group III (n = 60) 0.25% (w/w) chol diet + atorv for the development of calcification by MicroCT and Synchrotron MicroCT Scan and by Masson trichrome stain. Finally gene expression for Lrp5, Lrp6, and Runx2 PCR was performed to evaluate the expression in the control and the cholesterol valves. The ApoE(-/-) cholesterol treated mice developed calcification and increase in Lrp5, Runx2 (P < 0.05) as compared to control. The Lrp5(-/-) mice developed no calcification by MicroCT and Synchrotron and positive gene expression for Lrp5/6 or Runx2. The double knockout ApoE(-/-):Lrp5(-/-) developed mild mineralization in the cholesterol treated valves with an increase in Lrp6 and Runx2 expression(P < 0.05). There was no mineralization in the right sided hearts valves. In conclusion Lrp5/6 is necessary for calcification in the aortic valve in the presence of experimental hypercholesterolemia. These data demonstrate the first mouse genetic evidence for the LDL-Density-Pressure theory in cardiac valves.

摘要

Lrp5/6 共受体已知在骨形成和脂质代谢中发挥作用。该基因编码 LDL 受体基因家族的成员。本研究检验了以下假设:Lrp5/6 对于实验性高胆固醇血症中瓣钙化的发展是必需的。测试了实验性高胆固醇血症小鼠模型:Lrp5(-/-)/ApoE(-/-):Lrp5(-/-)/ApoE(-/-) 小鼠(n = 180)。I 组(n = 60)正常饮食,II 组(n = 60)0.25% 胆固醇饮食(w/w),III 组(n = 60)0.25%(w/w)胆固醇饮食+阿托伐他汀用于通过 MicroCT 和同步辐射 MicroCT 扫描和 Masson 三色染色评估钙化的发展。最后进行了 Lrp5、Lrp6 和 Runx2 PCR 的基因表达,以评估对照和胆固醇瓣膜中的表达。与对照组相比,ApoE(-/-)胆固醇处理的小鼠发生钙化并增加 Lrp5、Runx2(P < 0.05)。Lrp5(-/-)小鼠通过 MicroCT 和同步辐射未发生钙化,Lrp5/6 或 Runx2 的基因表达呈阳性。双敲除 ApoE(-/-):Lrp5(-/-)在胆固醇处理的瓣膜中发生轻度矿化,Lrp6 和 Runx2 表达增加(P < 0.05)。右侧心脏瓣膜没有矿化。总之,在实验性高胆固醇血症存在的情况下,Lrp5/6 是主动脉瓣钙化所必需的。这些数据提供了 LDL-密度-压力理论在心脏瓣膜中首次小鼠遗传证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12c/3263342/587c54f677d9/nihms305970f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12c/3263342/587c54f677d9/nihms305970f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f12c/3263342/587c54f677d9/nihms305970f1.jpg

相似文献

1
The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/- /Lrp5-/- mice.Lrp5/6 在心脏瓣膜病中的作用:载脂蛋白 E 基因敲除 /Lrp5 基因敲除小鼠的实验性高胆固醇血症。
J Cell Biochem. 2011 Oct;112(10):2987-91. doi: 10.1002/jcb.23221.
2
TIEG1 is upregulated in Lrp5/6-mediated valve osteogenesis.TIEG1 在 Lrp5/6 介导的瓣膜骨发生中上调。
J Cell Biochem. 2019 Mar;120(3):3362-3366. doi: 10.1002/jcb.27606. Epub 2018 Sep 23.
3
Oxidative-mechanical stress signals stem cell niche mediated Lrp5 osteogenesis in eNOS(-/-) null mice.氧化-机械应激信号源于内皮型一氧化氮合酶(eNOS)缺失型小鼠骨髓间充质干细胞龛,介导 Lrp5 成骨作用。
J Cell Biochem. 2012 May;113(5):1623-34. doi: 10.1002/jcb.24031.
4
Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E.缺乏低密度脂蛋白受体相关蛋白5和载脂蛋白E的小鼠出现严重高胆固醇血症、脂肪耐量受损及晚期动脉粥样硬化。
J Biol Chem. 2003 Mar 28;278(13):11331-6. doi: 10.1074/jbc.M211987200. Epub 2002 Dec 31.
5
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.阿托伐他汀通过低密度脂蛋白受体相关蛋白5(Lrp5)受体途径抑制高胆固醇血症诱导的主动脉瓣钙化。
Circulation. 2005 Aug 30;112(9 Suppl):I229-34. doi: 10.1161/01.CIRCULATIONAHA.104.524306.
6
Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.Lrp5 和 Lrp6 在骨细胞中发挥重叠功能,促进出生后骨量的获得。
PLoS One. 2013 May 10;8(5):e63323. doi: 10.1371/journal.pone.0063323. Print 2013.
7
Retinoic acid disrupts osteogenesis in pre-osteoblasts by down-regulating WNT signaling.维甲酸通过下调 WNT 信号干扰前成骨细胞的成骨作用。
Int J Biochem Cell Biol. 2019 Nov;116:105597. doi: 10.1016/j.biocel.2019.105597. Epub 2019 Aug 31.
8
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.人类退行性瓣膜病与低密度脂蛋白受体相关蛋白5受体介导的骨形成上调有关。
J Am Coll Cardiol. 2006 Apr 18;47(8):1707-12. doi: 10.1016/j.jacc.2006.02.040. Epub 2006 Mar 20.
9
SP7 transcription factor ameliorates bone defect healing in low-density lipoprotein receptor-related protein 5 (LRP5)-dependent osteoporosis mice.SP7转录因子改善低密度脂蛋白受体相关蛋白5(LRP5)依赖性骨质疏松症小鼠的骨缺损愈合。
J Zhejiang Univ Sci B. 2025 Mar 1;26(3):254-268. doi: 10.1631/jzus.B2300531.
10
The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory.LRP5/6 在心脏瓣膜病中的作用:LDL 密度-压力理论。
J Cell Biochem. 2011 Sep;112(9):2222-9. doi: 10.1002/jcb.23182.

引用本文的文献

1
AMBP protects against aortic valve calcification by inhibiting ERK1/2 and JNK pathways mediated by FHL3.AMBP通过抑制由FHL3介导的ERK1/2和JNK信号通路来预防主动脉瓣钙化。
Theranostics. 2025 Mar 18;15(10):4398-4415. doi: 10.7150/thno.109182. eCollection 2025.
2
Unraveling the Mechanisms of Valvular Heart Disease to Identify Medical Therapy Targets: A Scientific Statement From the American Heart Association.解开瓣膜性心脏病的机制,以确定医学治疗靶点:美国心脏协会的科学声明。
Circulation. 2024 Aug 6;150(6):e109-e128. doi: 10.1161/CIR.0000000000001254. Epub 2024 Jun 17.
3
Nanocarriers of shRNA-Runx2 directed to collagen IV as a nanotherapeutic system to target calcific aortic valve disease.

本文引用的文献

1
The role of Lrp5/6 in cardiac valve disease: LDL-density-pressure theory.LRP5/6 在心脏瓣膜病中的作用:LDL 密度-压力理论。
J Cell Biochem. 2011 Sep;112(9):2222-9. doi: 10.1002/jcb.23182.
2
TIEG-null mice display an osteopenic gender-specific phenotype.TIEG基因缺失的小鼠表现出骨质疏松的性别特异性表型。
Bone. 2008 Jun;42(6):1025-31. doi: 10.1016/j.bone.2008.02.004. Epub 2008 Mar 4.
3
LRP6 mutation in a family with early coronary disease and metabolic risk factors.一个患有早发性冠心病和代谢危险因素的家族中的低密度脂蛋白受体相关蛋白6(LRP6)突变
作为一种靶向钙化性主动脉瓣疾病的纳米治疗系统,将shRNA-Runx2靶向胶原蛋白IV的纳米载体。
Mater Today Bio. 2023 Mar 28;20:100620. doi: 10.1016/j.mtbio.2023.100620. eCollection 2023 Jun.
4
Upregulation of miR-664a-3p Ameliorates Calcific Aortic Valve Disease by Inhibiting the BMP2 Signaling Pathway.miR-664a-3p 的上调通过抑制 BMP2 信号通路改善了钙化性主动脉瓣疾病。
Dis Markers. 2022 Oct 7;2022:2074356. doi: 10.1155/2022/2074356. eCollection 2022.
5
miRNA Expression Profiling Uncovers a Role of miR-139-5p in Regulating the Calcification of Human Aortic Valve Interstitial Cells.微小RNA表达谱分析揭示了miR-139-5p在调节人主动脉瓣间质细胞钙化中的作用。
Front Genet. 2021 Oct 22;12:722564. doi: 10.3389/fgene.2021.722564. eCollection 2021.
6
Role of oxidative stress in calcific aortic valve disease and its therapeutic implications.氧化应激在钙化性主动脉瓣疾病中的作用及其治疗意义。
Cardiovasc Res. 2022 May 6;118(6):1433-1451. doi: 10.1093/cvr/cvab142.
7
Low-density lipoprotein receptor-related protein 6-mediated signaling pathways and associated cardiovascular diseases: diagnostic and therapeutic opportunities.载脂蛋白 B 降解通路相关蛋白 6 介导的信号通路与心血管疾病:诊断与治疗的新契机。
Hum Genet. 2020 Apr;139(4):447-459. doi: 10.1007/s00439-020-02124-8. Epub 2020 Feb 19.
8
HDAC I inhibitor regulates RUNX2 transactivation through canonical and non-canonical Wnt signaling in aortic valvular interstitial cells.组蛋白去乙酰化酶I抑制剂通过主动脉瓣间质细胞中经典和非经典Wnt信号通路调节RUNX2反式激活。
Am J Transl Res. 2019 Feb 15;11(2):744-754. eCollection 2019.
9
MMP-12-Induced Pro-osteogenic Responses in Human Aortic Valve Interstitial Cells.MMP-12 诱导的人主动脉瓣间质细胞成骨反应。
J Surg Res. 2019 Mar;235:44-51. doi: 10.1016/j.jss.2018.09.005. Epub 2018 Oct 23.
10
Treatment with XAV-939 prevents in vitro calcification of human valvular interstitial cells.XAV-939 治疗可预防人瓣膜间质细胞的体外钙化。
PLoS One. 2018 Dec 7;13(12):e0208774. doi: 10.1371/journal.pone.0208774. eCollection 2018.
Science. 2007 Mar 2;315(5816):1278-82. doi: 10.1126/science.1136370.
4
Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation.人类退行性瓣膜病与低密度脂蛋白受体相关蛋白5受体介导的骨形成上调有关。
J Am Coll Cardiol. 2006 Apr 18;47(8):1707-12. doi: 10.1016/j.jacc.2006.02.040. Epub 2006 Mar 20.
5
Parameters of LRP5 from a structural and molecular perspective.从结构和分子角度看LRP5的参数。
Crit Rev Eukaryot Gene Expr. 2005;15(3):229-42. doi: 10.1615/critreveukargeneexpr.v15.i3.50.
6
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.阿托伐他汀通过低密度脂蛋白受体相关蛋白5(Lrp5)受体途径抑制高胆固醇血症诱导的主动脉瓣钙化。
Circulation. 2005 Aug 30;112(9 Suppl):I229-34. doi: 10.1161/01.CIRCULATIONAHA.104.524306.
7
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.阿托伐他汀可抑制高胆固醇血症主动脉瓣钙化并增强一氧化氮合酶的生成。
Heart. 2005 Jun;91(6):806-10. doi: 10.1136/hrt.2003.029785.
8
Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals.Msx2 通过激活旁分泌 Wnt 信号促进心血管钙化。
J Clin Invest. 2005 May;115(5):1210-20. doi: 10.1172/JCI24140. Epub 2005 Apr 14.
9
Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.携带Lrp5和Lrp6双突变的小鼠出现骨密度降低和肢体畸形。
J Bone Miner Res. 2004 Dec;19(12):2033-40. doi: 10.1359/JBMR.040907. Epub 2004 Sep 13.
10
LRP5 and Wnt signaling: a union made for bone.低密度脂蛋白受体相关蛋白5(LRP5)与Wnt信号通路:骨骼的完美组合
J Bone Miner Res. 2004 Nov;19(11):1749-57. doi: 10.1359/JBMR.040816. Epub 2004 Aug 23.